Osteoporosis Therapeutics

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation and Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study
• Bisphosphonates
• Hormone Replacement Therapy/Estrogen Replacement Therapy
• Estrogens
• Estrogens/Progesterones
• Calcitonins
• Selective Estrogen Receptor Modulators (SERMs)
• Other Therapeutics

II. EXECUTIVE SUMMARY

1. Outlook

• Regional Market Perspective
• United States
• Europe
• Japan

2. Industry Overview

• Osteoporosis Therapeutics: An Evolutionary Scan
• “A Sketch of the Present Industry Scenario”
• Facts & Figures: The Osteoporosis Primacy
• Snapshots
• Table 1: Prevalence of Osteoporosis and Osteopenia in Major Markets including US, Germany, Italy, France, UK, Spain and Japan: 2003-2013 (In Millions) (includes corresponding Graph/Chart)
• Factors Influencing Demand
• Competitive Landscape
• Table 2: Worldwide Osteoporosis Market (2006): Percentage Breakdown by Leading Players-Merck, Novartis, Eli Lilly, Procter & Gamble, Wyeth, and Others (includes corresponding Graph/Chart)
• Table 3: Worldwide Osteoporosis Market (2005): Dollar Sales of Leading Osteoporosis Drugs-Fosamax, Actonel, Evista, Miacalcic, and Forteo (In US$ Thousands) (includes corresponding Graph/Chart)
• Table 4: Leading Osteoporosis Therapies and its Cost per Day
• Market Trends and Issues
• Can New Treatments Beat the Gold Standard?
• Oral Calcitonin Likely to Emerge as Wonder Drug
• New Bisphosphonates Challenge Established Brands
• Side Effects of HRT Fuel Natural Alternatives Sales
• Bone Formation Drugs Augur New Prospects
• A Sneak Into Various Options in Antiresorptives, Anabolic Therapeutics
• Estrogen Replacement Therapy: Will Dosing Make a Difference?
• Is Prevention Always Better Than Cure?
• Peptide-Based Osteoporosis Therapy Gaining Ground
• Polymorphism- A Potent Diagnostic Marker
• Bisphosphonates - The Other Side
• Efficacy of Evista Under the Scanner

3. Major Therapeutic Classes: A Global Perspective

• ERT Drugs
• Ups and Downs in the ERT Market
• Outlook
• Bisphosphonates
• The leading Therapeutic Market.
• SERMS
• Market Overview
• Calcitonins
• Market Overview

4. Product Overview

• The “Silent Thief”
• An Introduction to Bone Physiology
• How Osteoporosis Steps In
• Osteoporosis: Major Types
• Primary Osteoporosis
• Secondary Osteoporosis
• Osteoporosis - The Aftermath
• Prevention: The Only Better Way Out
• Osteoporosis Therapies: A Cursory Glance
• Nondrug Therapy
• Drug Therapy
• Major Osteoporosis Therapeutic Classes: A Brief Review
• Bisphosphonates
• Classification of Bisphosphonates
• Etidronate
• Alendronate
• Risedronate
• Calcitonin: A Relatively Safer Therapeutic
• What It Is
• What It Does
• Major Types
• Salmon Calcitonin
• SERM: A Breakthrough
• Raloxifene: The First SERM
• SERMs: The Positive Angle
• SERMs: The Negative Side
• Hormone Replacement Therapy/Estrogen Replacement Therapy: The Longstanding Therapeutic
• ERT: The Positive Side
• The Negative Angle to ERT
• Tereparatide: The First Anabolic Agent
• Composition
• Forteo: A Leading Brand
• Major Therapeutic Classes at a Glance
• Osteoporosis Therapeutics: A Peek into the Major Brands
• New Drugs/Drug Classes in Pipeline
• SERMs
• Bisphosphonates
• Zoledronic Acid:
• Pamidronate:
• Reclast
• Calcitonin
• Parathyroid Hormone (PTH)
• Denosumab (AMG-162)
• Combination Therapy

5. Major Clinical Trials/Findings

• End-Stage Therapies (Under Development) for Osteoporosis Prevention/Cure
• GSK & NPS Collaborate for Phase II Clinical Study of Calcilytics
• Radius Initiates Phase II Trials for BA058
• Novartis and Nordic Initiate Phase III Clinical Trial of Oral Salmon Calcitonin
• Medivir Initiates First Human Trials for MIV-701
• Osteologix Begins Phase II Trial of NB S101
• Zelos and Nektar Initiates Phase I Clinical Trial of Ostabolin-C™
• Acceleron Initiates Phase I Clinical Trial of ACE-011
• Positive Results from Reclast Clinical Trials

6. Product Introductions/Approvals

• P&G Receives FDA Approval for New Dosage of Actonel
• Takeda Introduces Benet® for Osteoporosis Treatment
• Labtec Obtains Approval to Market Hormone Replacement Patch in Europe
• Wyeth Obtains Conditional Approval for Osteoporosis Drug from FDA
• Merck’s New Dosage of FOSAMAX PLUS D Gains FDA Approval
• Japanese Pharma Majors Receive Approval for Generic Osteoporosis Drug
• Roche and GlaxoSmithKline Introduce Bonviva
• GlaxoSmithKline and Roche Co-Promoted Boniva Receives FDA Approval
• Nycomed’s Preotact Recommended for Approval in Europe
• Procter & Gamble and Sanofi-Aventis’ Actonel Approved for Male Osteoporosis
• Upsher-Smith Laboratories Rolls Out Fortical Nasal Spray
• Teva Receives Tentative FDA Approval for Risedronate Sodium Tablets
• GlaxoSmithKline and Roche Receive Approval for Bonviva in Switzerland
• Roche’s Once-a-month Bisphosphonate Gets FDA Nod
• Actonel with Calcium® Obtains FDA Approval
• FDA Approves Unigene’s Nasal Calcitonin
• Novavax’s ESTRASORB® Clears FDA Hurdle
• Menostar™ Secures FDA Approval
• Bonviva Gains European Commission Approval
• Schering Introduces New Hormone Therapy Products
• Eli Lilly Launches Evista in Japan and China
• Proteolos Bags EU Approval
• Forcaltonin® Secures European Approval
• Ministry of Health Labor and Welfare Approves P&G’s Actonel®
• Eli Lilly’s Osteoporosis Drug Obtains US Approval
• Vivelle Dot 0.025 ERT Patch from Novogyne
• Novartis Rolls Out Estradot
• Pfizer Launches FemHRT
• Ligand Unveils LGD2226

7. Recent Industry Activity

• Schering-Plough Acquires Organon BioSciences
• Faes Farma Signs Marketing Agreement with Roche and GlaxoSmithKline
• Alethia and Emerillon Collaborate on Osteoporosis Therapies
• Ipsen Enters into Co-marketing Agreement with MSD
• Unigene Enters into Agreement with Novartis
• Pharming Group Granted Subsidies to Develop Osteoporosis Drugs
• Procter & Gamble Terminates Nasal Spray Collaboration with Nastech Pharmaceutical
• Pharming Group Acquires Dnage
• Amgen Acquires Abgenix
• P&G Licenses Osteoporosis Nasal Spray Rights from Nastech
• Eli Lilly to Close Basingstoke Plant
• Galapagos Acquires Drug Discovery Platform of Discovery Partners
• Duravest Acquires Bio-Magnetic Therapy
• Galapagos Acquires ProStrakan’s ProSkelia
• Roche Inks a Marketing Agreement with Elder Pharma
• Chugai and Taisho Sign a Joint Development and Marketing Agreement
• Theragenex Signs a Licensing Agreement with Zylera
• Radius Acquires Licensing Agreement for Eisai’s SERMs
• Alkermes Partners with Eli Lilly to Develop and Market PTH Formulation
• Radius Acquires Exclusive Rights to Karo Bio’s SARMS
• Unigene Enters into Agreement with Tzamal Bio
• Galapagos Acquires Inpharmatica
• Bio-Rad Acquires Provalis Medical Diagnostics Operations
• Daiichi Sankyo to Market Evista in Europe
• Biocon Acquires Nobex
• Radius and Ipsen Enters into Licensing Agreement
• Novartis Acquires Hexal AG
• Nippon Chemiphar Signs Agreement with Velcura Therapeutics
• Biopotential Capital Acquires Osta Biopharma
• Dnage Commences DNA Research Programme for Osteoporosis Therapeutics
• Nastech Initiates Phase I Study of PTH 1-34
• SEQUENOM Collaborates with P&G Pharmaceuticals
• Novartis Extends Alliance with Emisphere
• Eli Lilly Markets Forteo in Europe
• Avesthagen Co-develops Osteoporosis Drug with CCBR
• Nastech Signs Agreement with Par Pharmaceutical, Inc
• Unigene and Novartis in a Licensing and Manufacturing Agreement

8. Developments in the Recent Past

• Wyeth Ties Up with Tanox and Galapagos
• Galapagos and P&G Collaborate to Develop Osteoporosis Drugs
• Unigene Grants License to Faran
• Genome Collaborates with Amgen
• Unigene Joins Hands with Shijiazhuang
• Unigene, GSK Signs License Collaboration
• Unigene and Upsher-Smith in a Licensing Agreement
• Celgene and Novartis Embark on Joint Research for SERMs
• Roche, GSK Signs Global Agreement
• Novogyne Procures CombiPatch™ from Aventis

9. Focus on Select Global Players

• Eli Lilly and Company (US)
• F.Hoffmann-La Roche Ltd (Switzerland)
  • Merck & Co., Inc. (US)
  • Novartis AG (Switzerland)
  • Novo Nordisk A/S (Denmark)
  • Organon
  • Procter & Gamble Pharmaceuticals Inc. (US)
  • Sanofi-Aventis SA (France)
  • Servier SA (France)
  • Solvay Pharmaceuticals Inc. (US)
  • Unigene Laboratories, Inc. (US)
  • Wyeth (US)

10. Global Market Perspective

• Table 5: World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 6: World Long-Term Projections for Osteoporosis Therapeutics by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 7: World 10-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)
• Table 8: World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 9: World Long-Term Projections for Bisphosphonates by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 10: World 10-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)
• Table 11: World Recent Past, Current & Future Analysis for ERT Drugs by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 12: World Long-Term Projections for ERT Drugs by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 13: World 10-Year Perspective for ERT Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)
• Table 14: World Recent Past, Current & Future Analysis for SERMs by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 15: World Long-Term Projections for SERMs by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 16: World 10-Year Perspective for SERMs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)
• Table 17: World Recent Past, Current & Future Analysis for Calcitonins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 18: World Long-Term Projections for Calcitonins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 19: World 10-Year Perspective for Calcitonins by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

III. MARKET

1. United States

• A. Market Analysis
  • Industry Overview
  • Outlook
  • Osteoporosis in the US: An Insight
  • Osteoporosis - An Underserved Market?
  • Statistical Review
  • Table 20: Incidence of Osteoporosis in the US (2004) (includes corresponding Graph/Chart)
  • Table 21: Osteoporosis Prevalence in Post-Menopause Women (includes corresponding Graph/Chart)
  • Table 22: Number of Osteoporosis Patients Undergoing Osteoporosis Therapies (In Thousands) (includes corresponding Graph/Chart)
  • Osteoporosis Prescription Market
  • Table 23: US Osteoporosis Prescription Market (2004-2006): Percentage Share of Leading Drugs- Fosamax, Actonel, Evista, Boniva, Forteo and Others (includes corresponding Graph/Chart)
  • Competitive Scenario
  • Table 24: Leading Players in the US Osteoporosis Market (2004) - Market Share by Value Sales for Merck, Eli Lilly, Procter & Gamble/ Sanofi-Aventis and Others (includes corresponding Graph/Chart)
  • Competitive Review by Segment
  • Bisphosphonates
  • Table 25: Leading Players in the US Bisphosphonates Market (2004) - Market Share by Value Sales for Merck and Procter & Gamble/ Sanofi-Aventis
  • Table 26: Leading Players in the US Bisphosphonates Market (2008) - Market Share by Value Sales for Merck, Procter & Gamble/ Sanofi-Aventis, Novartis and Roche/GSK (includes corresponding Graph/Chart)
  • SERMs
  • Calcitonins
  • Patent Expiry Catalog of Major OsteoporosisDrugs
  • Product Launches/Approvals
  • Strategic Corporate Developments
  • Select US Players
• B. Market Analytics
  • Table 27: US Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, Calcitonins and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 28: US Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, Calcitonins and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 29: US 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins and Others for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

2. Japan

• A. Market Analysis
  • Product Launches/Approvals
  • Strategic Corporate Development
• B. Market Analytics
  • Table 30: Japanese Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 31: Japanese Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 32: Japanese 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

3. Europe

• A. Market Analysis
  • Outlook
  • Forsteo: The First Anabolic Agent in Europe
  • European Regulatory Restricts HRT
  • Calcitonins Embraces New Label
  • Table 33: European Market for Osteoporosis Therapeutics (2005): Market Share of Leading Players - Novartis, Merck, Wyeth, Novo Nordisk, Organon, Procter & Gamble, Schering, Solvay and Others (includes corresponding Graph/Chart)
  • Product Launches/Approvals
  • Strategic Corporate Developments
  • Select European Players
• B. Market Analytics
  • Table 34: European Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Geographic Region - France, Germany, The UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 35: European Long-Term Projections for Osteoporosis Therapeutics by Geographic Region - France, Germany, The UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 36: European 10-Year Perspective for Osteoporosis Therapeutics by Geographic Regions - Percentage Breakdown of Dollar Sales for France, Germany, The UK, Italy, Spain, and Rest of Europe Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)
  • Table 37: European Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 38: European Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 39: European 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

3a. France

• A. Market Analysis
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 40: French Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 41: French Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 42: French 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

3b. Germany

• Market Analysis
• Table 43: German Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 44: German Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 45: German 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

3c. The United Kingdom

• A. Market Analysis
  • Osteoporosis Population Forecast in the UK
  • Osteoporosis Population in the UK: 2004 -2009E
  • Product Launches
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 46: UK Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 47: UK Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 48: UK 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

3d. Italy

• Market Analysis
• Table 49: Italian Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 50: Italian Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 51: Italian 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

3e. Spain

• A. Market Analysis
  • Strategic Corporate Development
• B. Market Analytics
  • Table 52: Spanish Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 53: Spanish Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 54: Spanish 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

3f. Rest of Europe

• A. Market Analysis
  • Outlook
  • Romania
  • Strategic Corporate Developments
  • Select Players in Rest of Europe
• B. Market Analytics
  • Table 55: Rest of Europe Market for Osteoporosis Therapeutics - Recent Past, Current & Future Analysis by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 56: Rest of Europe Long-Term Projections for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 57: Rest of Europe 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

4. Rest of World

• A. Market Analysis
  • Outlook
  • Prevalence of Osteoporosis in VariousRegion-At a Glance
  • Korea
  • Table 58: Leading Brands in the Korean Osteoporosis Therapeutics Market (2005): Percentage Share Breakdown by Dollar Sales for Fosamax, Atonel, Alend, Maxmarvil, and Others (includes corresponding Graph/Chart)
  • China
  • Schering Pharmaceutical Limited (China) -A Major Player
  • Product Launch
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 59: Rest of World Market for Osteoporosis Therapeutics - Recent Past, Current & Future Analysis by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 60: Rest of World Long-Term Projections for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 61: Rest of World 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE